Zydus Receives Final Fda Approval For Type 2 Diabetes Drug
The Drug Is Used To Improve Glycemic Control And Lower The Risk Of Cardiovascular Death In Adults With Type 2 Diabetes. Zydus Lifesciences Ltd Has Received Final Fda Approval To Market Empagliflozin And Metformin Hydrochloride Tablets In 5 Mg/500 Mg, 5 Mg/1000 Mg, 12.5 Mg/500 Mg, And 12.5 Mg/1000 Mg Strengths (Us Rld: Synjardy). Empagliflozin And Metformin Hydrochloride Tablets Are Used With Proper Diet And Exercise To Improve Glycemic Control In Adults With Type 2 Diabetes Mellitus. They Are Also Used To Lower The Risk Of Cardiovascular Death In Patients With Type 2 Diabetes Mellitus And Established Cardiovascular Disease. The Drug Will Be Manufactured At The Group
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!